MedPage Today on MSN3d
Deciding Whether Multiple Sclerosis Treatment Should Be DiscontinuedObservational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosisIf approved, tolebrutinib would be ...
Tolebrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory ...
Sanofi’s tolebrutinib has been accepted for priority review by the US Food and Drug Administration (FDA) to treat certain ...
A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...
Using 3T MRI to analyze central vein counts and distribution in white matter lesions allows investigators to distinguish multiple sclerosis from migraine pathology. Medscape Medical News ...
The ratio of two types of bacteria in the gut microbiome may be able to predict disease severity in multiple sclerosis, ...
Gabryelle “Gabby” Scholfield, a 16-year-old student-athlete at Edmondson Westside High School in Baltimore, who plays center ...
Live Science on MSN4d
In a 1st, trial finds vitamin D supplements may slow multiple sclerosis. But questions remain.A new clinical trial has shown for the first time that taking high doses of vitamin D could stave off the progression of ...
A significant benefit was observed with Tysabri over Rebif in delaying SPMS disability progression when therapeutic lag was ...
US FDA accepts for priority review Sanofi’s regulatory submission of tolebrutinib for patients with multiple sclerosis: Paris Wednesday, March 26, 2025, 09:00 Hrs [IST] The US F ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback